This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Aug;13(8):466.

doi: 10.1038/nrclinonc.2016.112. Epub 2016 Jul 12.

Haematological cancer: Obinutuzumab effective against treatment-refractory NHL

PMID: 27402577
DOI: 10.1038/nrclinonc.2016.112

Comment

Haematological cancer: Obinutuzumab effective against treatment-refractory NHL

Peter Sidaway. Nat Rev Clin Oncol. 2016 Aug.

. 2016 Aug;13(8):466.

doi: 10.1038/nrclinonc.2016.112. Epub 2016 Jul 12.

Author

PMID: 27402577
DOI: 10.1038/nrclinonc.2016.112

No abstract available

PubMed Disclaimer

Comment on

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Sehn LH, et al. Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23. Lancet Oncol. 2016. PMID: 27345636 Clinical Trial.

References

1. Lancet Oncol. 2016 Aug;17 (8):1081-93 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations